ARWR ARROWHEAD PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 879407 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $38.04M 20 sales by 10 insiders
- Filings on record
- 139 since 2021-09-10, latest 2026-08-20 17:25
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Anzalone Christopher Richard | CEO, Dir | — | $24.01M |
| Hamilton James C | Chief Medical Off | — | $4.63M |
| O'Brien Patrick | COO | — | $3.12M |
| PERRY MICHAEL S | Dir | — | $2.00M |
| Ferrari Mauro | Dir | — | $1.02M |
| Apel Daniel Joseph | CFO | — | $934.3K |
| OLUKOTUN ADEOYE Y | Dir | — | $850.5K |
| Vakiener Victoria | Dir | — | $679.5K |
| Waddill William D. | Dir | — | $566.0K |
| Lu Hongbo | Dir | — | $228.3K |
Transactions 165
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 17:25 | 2026-08-18 | ARWR | OLUKOTUN ADEOYE Y | Dir | S - Sale | $86.96 | -2,000 | 31.6K | -6% | -$173.9K | |
| 2026-08-20 17:22 | 2026-08-18 | ARWR | PERRY MICHAEL S | Dir | S - Sale | $87.30 | -11.6K | 111.5K | -9% | -$1.01M | |
| 2026-06-17 21:44 | 2026-06-15 | ARWR | Cohen Matthew Gregory | Dir | A - Grant | $0.00 | +11.9K | 11.9K | New | $0 | |
| T | 2026-05-14 19:05 | 2026-05-12 | ARWR | Lu Hongbo | Dir | S - Sale | $76.88 | -2,970 | 52.0K | -5% | -$228.3K |
| MT | 2026-04-24 18:44 | 2026-04-22 | ARWR | Apel Daniel Joseph | CFO | S - Sale | $71.35 | -13.1K | 162.9K | -7% | -$934.3K |
| T | 2026-04-24 18:38 | 2026-04-23 | ARWR | Hamilton James C | Chief Medical Off | S - Sale | $75.00 | -10.0K | 227.0K | -4% | -$750.0K |
| 2026-03-09 | 2026-03-05 | ARWR | Hamilton James C | Chief Medical Off | S - Sale | $64.19 | -10.0K | 237.0K | -4% | -$641.9K | |
| 2026-01-08 | 2026-01-06 | ARWR | Hamilton James C | Chief Medical Off | A - Grant | $0.00 | +75.0K | 247.0K | +44% | $0 | |
| 2026-01-08 | 2026-01-06 | ARWR | Apel Daniel Joseph | CFO | A - Grant | $0.00 | +75.0K | 176.2K | +74% | $0 | |
| M | 2026-01-08 | 2026-01-06 | ARWR | O'Brien Patrick | COO | G - Gift | $0.00 | -2,500 | 472.8K | -0.5% | $0 |
| 2026-01-08 | 2026-01-06 | ARWR | O'Brien Patrick | COO | A - Grant | $0.00 | +75.0K | 547.4K | +16% | $0 | |
| M | 2026-01-05 | 2026-01-02 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $66.10 | -13.2K | 3.80M | -0.3% | -$871.7K |
| M | 2026-01-05 | 2025-12-31 | ARWR | O'Brien Patrick | COO | G - Gift | $0.00 | -2,800 | 526.1K | -0.5% | $0 |
| M | 2026-01-05 | 2026-01-05 | ARWR | O'Brien Patrick | COO | S - Sale | $63.11 | -49.5K | 475.0K | -9% | -$3.12M |
| M | 2026-01-05 | 2026-01-05 | ARWR | Hamilton James C | Chief Medical Off | S - Sale | $63.11 | -40.2K | 173.9K | -19% | -$2.53M |
| DM | 2025-12-30 | 2025-12-29 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale+OE | $69.13 | -51.7K | 3.82M | -1% | -$3.58M |
| DM | 2025-12-30 | 2025-12-29 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $6.15 | +51.7K | 3.84M | +1% | +$318.1K |
| 2025-12-30 | 2025-12-26 | ARWR | Ferrari Mauro | Dir | S - Sale | $70.00 | -7,530 | 69.1K | -10% | -$527.1K | |
| M | 2025-12-23 | 2025-12-19 | ARWR | Vakiener Victoria | Dir | S - Sale | $67.68 | -10.0K | 37.7K | -21% | -$679.5K |
| M | 2025-12-23 | 2025-12-19+ | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $68.04 | -26.0K | 3.81M | -0.7% | -$1.77M |
| M | 2025-12-23 | 2025-12-19 | ARWR | Waddill William D. | Dir | S - Sale | $67.65 | -8,367 | 56.6K | -13% | -$566.0K |
| M | 2025-12-23 | 2025-12-19 | ARWR | OLUKOTUN ADEOYE Y | Dir | S - Sale | $67.66 | -10.0K | 33.6K | -23% | -$676.6K |
| M | 2025-12-19 | 2025-12-17 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $64.04 | -85.0K | 3.87M | -2% | -$5.44M |
| 2025-12-18 | 2025-12-16 | ARWR | Waddill William D. | Dir | A - Grant | $0.00 | +7,819 | 64.9K | +14% | $0 | |
| 2025-12-18 | 2025-12-16 | ARWR | Lu Hongbo | Dir | A - Grant | $0.00 | +7,819 | 55.0K | +17% | $0 | |
| 2025-12-18 | 2025-12-16 | ARWR | INGRAM DOUGLAS S | Dir | A - Grant | $0.00 | +7,819 | 46.2K | +20% | $0 | |
| 2025-12-18 | 2025-12-16 | ARWR | OLUKOTUN ADEOYE Y | Dir | A - Grant | $0.00 | +7,819 | 43.6K | +22% | $0 | |
| 2025-12-18 | 2025-12-16 | ARWR | Vakiener Victoria | Dir | A - Grant | $0.00 | +7,819 | 45.8K | +21% | $0 | |
| 2025-12-18 | 2025-12-16 | ARWR | Ferrari Mauro | Dir | A - Grant | $0.00 | +7,819 | 76.6K | +11% | $0 | |
| 2025-12-18 | 2025-12-16 | ARWR | PERRY MICHAEL S | Dir | A - Grant | $0.00 | +7,819 | 123.1K | +7% | $0 | |
| M | 2025-12-16 | 2025-12-15+ | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $67.00 | -184.3K | 3.92M | -4% | -$12.35M |
| 2025-12-16 | 2025-12-12 | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $0.00 | +180.0K | 4.10M | +5% | $0 | |
| 2025-12-09 | 2025-12-05 | ARWR | PERRY MICHAEL S | Dir | S - Sale | $61.03 | -16.2K | 115.2K | -12% | -$991.7K | |
| 2025-12-01 | 2025-11-28 | ARWR | Ferrari Mauro | Dir | S - Sale | $56.39 | -8,750 | 68.8K | -11% | -$493.4K | |
| 2025-10-03 | 2025-10-01 | ARWR | Hamilton James C | Chief Medical Off | S - Sale | $35.00 | -20.0K | 212.1K | -9% | -$700.0K | |
| 2025-09-16 | 2025-09-12 | ARWR | Hamilton James C | Chief Medical Off | S - Sale | $30.00 | -15.0K | 232.1K | -6% | -$450.0K | |
| 2025-09-04 | 2025-09-02 | ARWR | Hamilton James C | Chief Medical Off | S - Sale | $25.00 | -15.0K | 247.1K | -6% | -$375.0K | |
| M | 2025-08-15 | 2025-08-13+ | ARWR | Hamilton James C | Chief Medical Off | S - Sale | $20.00 | -10.0K | 262.1K | -4% | -$200.0K |
| M | 2025-04-11 | 2025-04-09+ | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $10.87 | -141.1K | 4.03M | -3% | -$1.53M |
| 2025-03-17 | 2025-03-13 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $15.07 | -51.4K | 4.06M | -1% | -$775.0K | |
| 2025-03-17 | 2025-03-13 | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $0.00 | +340.0K | 4.11M | +9% | $0 | |
| DM | 2025-03-05 | 2025-03-03+ | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $7.75 | +300.0K | 3.94M | +8% | +$2.33M |
| DM | 2025-03-05 | 2025-03-03+ | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale+OE | $17.58 | -300.0K | 3.77M | -7% | -$5.27M |
| 2025-02-10 | 2025-02-07 | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $20.10 | +9,550 | 3.77M | +0.3% | +$192.0K | |
| 2025-02-07 | 2025-02-06 | ARWR | INGRAM DOUGLAS S | Dir | A - Grant | $20.09 | +38.4K | 38.4K | New | +$771.4K | |
| 2025-01-27 | 2025-01-23 | ARWR | OLUKOTUN ADEOYE Y | Dir | S - Sale | $21.00 | -959 | 35.8K | -3% | -$20.1K | |
| M | 2025-01-07 | 2025-01-06+ | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $19.77 | -45.2K | 465.4K | -9% | -$893.1K |
| 2025-01-07 | 2025-01-04 | ARWR | Myszkowski Kenneth Allen | CFO | A - Grant | $0.00 | +100.0K | 500.6K | +25% | $0 | |
| M | 2025-01-07 | 2025-01-06+ | ARWR | O'Brien Patrick | COO, GC | S - Sale | $19.80 | -37.2K | 527.2K | -7% | -$736.1K |
| 2025-01-07 | 2025-01-04 | ARWR | O'Brien Patrick | COO, GC | A - Grant | $0.00 | +100.0K | 564.4K | +22% | $0 | |
| M | 2025-01-07 | 2025-01-06 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | S - Sale | $19.82 | -32.7K | 283.1K | -10% | -$648.8K |
| 2025-01-07 | 2025-01-04 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | A - Grant | $0.00 | +100.0K | 304.9K | +49% | $0 | |
| 2025-01-06 | 2025-01-02 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $19.05 | -11.5K | 3.76M | -0.3% | -$219.5K | |
| 2024-12-30 | 2024-12-27 | ARWR | OLUKOTUN ADEOYE Y | Dir | S - Sale | $20.00 | -2,850 | 36.7K | -7% | -$57.0K | |
| 2024-12-23 | 2024-12-23 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $19.59 | -12.6K | 3.78M | -0.3% | -$246.1K | |
| 2024-12-20 | 2024-12-18 | ARWR | PERRY MICHAEL S | Dir | A - Grant | $22.99 | +16.7K | 131.5K | +15% | +$384.7K | |
| 2024-12-20 | 2024-12-18 | ARWR | Vakiener Victoria | Dir | A - Grant | $22.99 | +16.7K | 37.9K | +79% | +$384.7K | |
| 2024-12-20 | 2024-12-18 | ARWR | Lu Hongbo | Dir | A - Grant | $22.99 | +16.7K | 47.2K | +55% | +$384.7K | |
| 2024-12-20 | 2024-12-18 | ARWR | OLUKOTUN ADEOYE Y | Dir | A - Grant | $22.99 | +16.7K | 39.6K | +73% | +$384.7K | |
| M | 2024-12-20 | 2024-12-18 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $21.24 | -26.7K | 3.69M | -0.7% | -$567.5K |
| 2024-12-20 | 2024-12-18 | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $0.00 | +100.0K | 3.79M | +3% | $0 | |
| 2024-12-20 | 2024-12-18 | ARWR | Ferrari Mauro | Dir | A - Grant | $22.99 | +16.7K | 77.5K | +28% | +$384.7K | |
| 2024-12-20 | 2024-12-18 | ARWR | Waddill William D. | Dir | A - Grant | $22.99 | +16.7K | 57.1K | +41% | +$384.7K | |
| 2024-12-18 | 2024-12-16 | ARWR | Vakiener Victoria | Dir | S - Sale | $21.91 | -8,994 | 21.2K | -30% | -$197.1K | |
| M | 2024-12-18 | 2024-12-16+ | ARWR | GIVEN DOUGLAS B | Dir | S - Sale | $21.91 | -5,547 | 124.7K | -4% | -$121.6K |
| M | 2024-12-18 | 2024-12-16+ | ARWR | Waddill William D. | Dir | S - Sale | $21.97 | -7,495 | 40.4K | -16% | -$164.7K |
| 2024-07-03 | 2024-07-02 | ARWR | Oliver Tracie | Chief Commercial Off | S - Sale | $25.28 | -9,394 | 127.1K | -7% | -$237.5K | |
| 2024-05-06 | 2024-05-02 | ARWR | Vakiener Victoria | Dir | S - Sale | $23.31 | -1,799 | 30.2K | -6% | -$41.9K | |
| 2024-04-03 | 2024-04-01 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | S - Sale | $28.03 | -6,000 | 204.9K | -3% | -$168.2K | |
| M | 2024-03-20 | 2024-03-18+ | ARWR | Lu Hongbo | Dir | P - Purchase | $27.66 | +3,000 | 32.7K | +10% | +$83.0K |
| 2024-03-08 | 2024-03-06 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $35.19 | -40.0K | 400.6K | -9% | -$1.41M | |
| D | 2024-02-02 | 2024-01-31 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $14.54 | +57.5K | 3.77M | +2% | +$836.0K |
| DM | 2024-02-02 | 2024-01-31 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale+OE | $32.35 | -57.5K | 3.73M | -2% | -$1.86M |
| M | 2024-01-17 | 2024-01-12 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | S - Sale | $36.89 | -7,940 | 210.9K | -4% | -$292.9K |
| M | 2024-01-16 | 2024-01-11 | ARWR | GIVEN DOUGLAS B | Dir | S - Sale | $38.06 | -2,911 | 130.8K | -2% | -$110.8K |
| M | 2024-01-16 | 2024-01-11 | ARWR | Vakiener Victoria | Dir | S - Sale | $38.10 | -4,720 | 32.0K | -13% | -$179.8K |
| M | 2024-01-16 | 2024-01-11 | ARWR | Waddill William D. | Dir | S - Sale | $38.07 | -3,934 | 49.2K | -7% | -$149.8K |
| M | 2024-01-16 | 2024-01-11 | ARWR | Ferrari Mauro | Dir | S - Sale | $38.06 | -3,147 | 61.8K | -5% | -$119.8K |
| 2024-01-08 | 2024-01-04 | ARWR | Oliver Tracie | Chief Commercial Off | A - Grant | $0.00 | +75.0K | 136.6K | +122% | $0 | |
| 2024-01-08 | 2024-01-05 | ARWR | Oliver Tracie | Chief Commercial Off | S - Sale | $33.89 | -74 | 136.5K | -0.1% | -$2,508 | |
| M | 2024-01-08 | 2024-01-05 | ARWR | San Martin Javier | Chief Medical Off | S - Sale | $35.26 | -8,303 | 206.0K | -4% | -$292.8K |
| 2024-01-08 | 2024-01-04 | ARWR | San Martin Javier | Chief Medical Off | A - Grant | $0.00 | +75.0K | 206.8K | +57% | $0 | |
| M | 2024-01-08 | 2024-01-05 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $35.27 | -16.1K | 455.3K | -3% | -$567.9K |
| 2024-01-08 | 2024-01-04 | ARWR | Myszkowski Kenneth Allen | CFO | A - Grant | $0.00 | +75.0K | 456.7K | +20% | $0 | |
| M | 2024-01-05 | 2024-01-03+ | ARWR | O'Brien Patrick | COO, GC | S - Sale | $34.36 | -33.2K | 402.2K | -8% | -$1.14M |
| 2024-01-05 | 2024-01-04 | ARWR | O'Brien Patrick | COO, GC | A - Grant | $0.00 | +85.0K | 487.2K | +21% | $0 | |
| M | 2024-01-05 | 2024-01-03+ | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | S - Sale | $34.69 | -38.4K | 228.8K | -14% | -$1.33M |
| 2024-01-05 | 2024-01-04 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | A - Grant | $0.00 | +75.0K | 250.9K | +43% | $0 | |
| M | 2024-01-04 | 2024-01-02 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $31.01 | -9,952 | 3.72M | -0.3% | -$308.6K |
| 2023-12-22 | 2023-12-20 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $28.54 | -12.0K | 3.73M | -0.3% | -$342.5K | |
| 2023-12-19 | 2023-12-15 | ARWR | Waddill William D. | Dir | A - Grant | $25.41 | +15.0K | 51.8K | +41% | +$380.8K | |
| 2023-12-19 | 2023-12-15 | ARWR | PERRY MICHAEL S | Dir | A - Grant | $25.41 | +15.0K | 114.8K | +15% | +$380.8K | |
| 2023-12-19 | 2023-12-15 | ARWR | OLUKOTUN ADEOYE Y | Dir | A - Grant | $25.41 | +15.0K | 22.9K | +191% | +$380.8K | |
| 2023-12-19 | 2023-12-15 | ARWR | Vakiener Victoria | Dir | A - Grant | $25.41 | +15.0K | 36.7K | +69% | +$380.8K | |
| 2023-12-19 | 2023-12-15 | ARWR | GIVEN DOUGLAS B | Dir | A - Grant | $25.41 | +15.0K | 132.6K | +13% | +$380.8K | |
| 2023-12-19 | 2023-12-15 | ARWR | Ferrari Mauro | Dir | A - Grant | $25.41 | +15.0K | 65.8K | +29% | +$380.8K | |
| M | 2023-11-22 | 2023-11-20 | ARWR | San Martin Javier | Chief Medical Off | S - Sale | $28.80 | -19.7K | 131.8K | -13% | -$567.3K |
| 2023-10-27 | 2023-10-25 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $24.21 | -24.3K | 3.74M | -0.6% | -$589.2K | |
| 2023-10-02 | 2023-09-28 | ARWR | Vakiener Victoria | Dir | S - Sale | $26.33 | -1,550 | 21.7K | -7% | -$40.8K | |
| DM | 2023-09-20 | 2023-09-18 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale+OE | $28.12 | -57.8K | 3.76M | -2% | -$1.62M |
Purchase Sale Sale after option exercise All abbreviations